CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents Clinical Implications of Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion: Role of Antegrade and Retrograde Crossing Techniques Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease A Special Report From the American Heart Association and American College of Cardiolog New AHA/ACC/HRS Guidance on Sudden Cardiac Death Prevention Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging

Original Research2018 Jun 29.[Epub ahead of print]

JOURNAL:Circulation. Article Link

Reappraisal of Reported Genes for Sudden Arrhythmic Death: An Evidence-Based Evaluation of Gene Validity for Brugada Syndrome

S. Mohsen Hosseini, Raymond Kim, Sharmila Udupa Keywords: Brugada syndrome; ClinGen; genetics; sudden death

ABSTRACT


BACKGROUND - Implicit in the genetic evaluation of patients with suspected genetic diseases is the assumption that the genes evaluated are causative for the disease based on robust scientific and statistical evidence. However, in the past 20 years considerable variability has existed in the study design and quality of evidence supporting reported gene-disease associations raising concerns of the validity of many published disease-causing genes. Brugada syndrome (BrS) is an arrhythmia syndrome with a risk of sudden death. More than 20 genes have been reported to cause BrS and are assessed routinely on genetic testing panels in the absence of a systematic, evidence-based evaluation of the evidence supporting the causality of these genes. 


METHODS - We evaluated the clinical validity of genes tested by diagnostic laboratories for BrS by assembling three gene curation teams. Using an evidence-based semi-quantitative scoring system of genetic and experimental evidence for gene-disease associations, curation teams independently classified genes as demonstrating Limited, Moderate, Strong or Definitive evidence for disease causation in BrS. The classification of curator teams was reviewed by a Clinical Domain Expert Panel who could modify the classifications based on their independent review and consensus. 


RESULTS - Of 21 genes curated for clinical validity, biocurators classified only 1 gene (SCN5A) as Definitive evidence, while all other genes were classified as Limited evidence. Following comprehensive review by the Clinical Domain Expert Panel, all 20 genes classified as Limited evidence were re-classified as Disputed in regards to any assertions of disease causality for BrS. 


CONCLUSIONS - Our results contest the clinical validity of all but one gene clinically tested and reported to be associated with BrS. These findings warrant a systematic, evidence-based evaluation for reported gene-disease associations prior to use in patient care.